Evidence map›Paper›PMID 31294388›Full record

ArticleJournal of the Canadian Association of Gastroenterology2019

The Impact of Inflammatory Bowel Disease in Canada 2018: IBD Research Landscape in Canada.

Keeley L Rose, Philip M Sherman, Jane Cooke-Lauder, Mina Mawani, Eric I Benchimol, Gilaad G Kaplan, Charles N Bernstein, Alain Bitton, Sanjay K Murthy, Geoffrey C Nguyen and 1 more

Abstract read
In one paragraph

Article in Journal of the Canadian Association of Gastroenterology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Keeley L RoseCanadian Institutes of Health Research Institute of Nutrition, Metabolism and Diabetes (CIHR-INMD), Toronto, Ontario, Canada.
Philip M ShermanCanadian Institutes of Health Research Institute of Nutrition, Metabolism and Diabetes (CIHR-INMD), Toronto, Ontario, Canada.
Jane Cooke-LauderBataleur Enterprises Inc., Toronto, Ontario, Canada.
Mina MawaniCrohn's and Colitis Canada, Toronto, Ontario, Canada.
Eric I BenchimolCanadian Gastro-Intestinal Epidemiology Consortium, Canada.ORCID 0000-0001-8855-3598
Gilaad G KaplanCanadian Gastro-Intestinal Epidemiology Consortium, Canada.
Charles N BernsteinCanadian Gastro-Intestinal Epidemiology Consortium, Canada.
Alain BittonCanadian Gastro-Intestinal Epidemiology Consortium, Canada.
Sanjay K MurthyCanadian Gastro-Intestinal Epidemiology Consortium, Canada.
Geoffrey C NguyenCanadian Gastro-Intestinal Epidemiology Consortium, Canada.
Kate LeeCrohn's and Colitis Canada, Toronto, Ontario, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHealth research in Canada is funded by government, health charities, foundations and industry. We investigated levels of IBD research funding and the scientific impact of this research in Canada between 2013 and 2017.

methodsAn analysis of global and Canadian funding in IBD research was conducted using the Canadian Institutes of Health Research (CIHR) Funded Research Database and UberResearch's Dimensions platform. Examples of priority-driven and investigator-initiated IBD research in Canada are provided. Bibliometric analysis was used to assess the quality of IBD research output in Canada.

resultsTotal funding for IBD research Canada between 2013 and 2017 was over $119 million Canadian dollars (CAD), with CIHR, the largest funder, contributing almost $66 million CAD, and Crohn's and Colitis Canada, investing more than $32 million CAD. This ranks Canada fourth internationally. A comparative analysis indicates that publications by Canadian IBD researchers have a greater impact than other Canadian and international comparators. When productivity and impact in IBD research are combined, Canada is among the top three in the world.

conclusionsInvestment in IBD research in Canada has resulted in the development of a strong collaborative group of researchers producing impactful, world-class research. On all measures of academic productivity and influence, Canada ranks in the top two or three internationally. The challenges ahead are to continue to fund innovative IBD research and grow the next generation of IBD researchers while moving research findings into changes in health policy and practice in order to benefit affected patients and their families-and ultimately, to find the cause(s) and identify the cure(s).

Indexed as

CIHRCrohn’s and Colitis CanadaGastroenterologyInflammatory bowel diseaseResearch capacity

Identifiers

PMID31294388
PMCPMC6512242

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.